ADC Antibodies
ADC antibodies act as the navigation system of ADC drugs and are primarily responsible for delivering payloads to target cells.
All Product Categories
-
ADC Antibodies Related Products (136)
Related Products (136)
-
Anti-PSMA Antibody
0 ImagesCat. No.: HY-P991204Purity: 98.91%Synonyms: ARX517 antibody
-
Enapotamab
0 ImagesSynonyms: Anti-AXL/UFO Reference Antibody (enapotamab)Enapotamab (Anti-AXL/UFO Reference Antibody) is an AXL/UFO-related antibody that can be used for synthesis of ADC molecule Enapotamab vedotin (HY-P99921).
-
Cantuzumab
0 ImagesCantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493).
-
Zocilurtatug
0 ImagesSynonyms: ZL-1310 AntibodyZocilurtatug (ZL-1310 Antibody) is a human monoclonal antibody targeting DLL3. Zocilurtatug serves as the targeting antibody component of antibody-drug conjugates (ADCs) and is used in research related to small cell lung cancer and neuroendocrine carcinoma. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
-
Rolinsatamab
0 ImagesCat. No.: HY-P99238CAS No.: 2095467-30-2Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an antibody-drug conjugate, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific drug attachment engineered cysteines (S239C). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (S239C).
-
Mecbotamab
0 ImagesSynonyms: BA301Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011).
-
Anti-SLC44A4 Antibody
0 ImagesCat. No.: HY-P991080Purity: ≥99.0%Synonyms: ASG-5ME Antibody; AGS-5M2Anti-SLC44A4 Antibody (ASG-5ME Antibody) is a SLC44A4 targeting antibody that can be used for synthesis of ADC ASG-5ME.
-
Lonigutamab
0 ImagesSynonyms: hz208F2-4Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody, serveing as a targeting vector for antibody-drug conjugates (ADCs). Lonigutamab causes G2-M phase cell cycle arrest and increases apoptosis in IGF-1R-overexpressing tumor cells. Lonigutamab demonstrates potent antitumor efficacy in IGF-1R-overexpressing xenograft models. Lonigutamab can be used for the study of Solid tumors with overexpression of IGF-1R and thyroid eye diseases.
-
Torvutatug
0 ImagesSynonyms: AZD5335 Antibody; INT-019Torvutatug (AZD5335 Antibody) is a human IgG1 κ monoclonal antibody against FRα, with an IC50 value of 7.4 nM against hFRα. Torvutatug can serve as an ADC antibody for the synthesis of ADC, such as AZD5335. Torvutatug is applicable to ovarian cancer-related research.
-
Tamrintamab
0 ImagesSynonyms: SC-003 mAb; SC-Mab003; SC34.28ss1Tamrintamab (SC-003 mAb, SC-Mab003, SC34.28ss1) is an ADC Antibody targeting to dipeptidase 3 (DPEP3 or MBD3). DPEP3 is a glycosyl phosphatidylinositol anchored metallopeptidase that is overexpressed in ovarian tumors. Tamrintamab can specifically bind DPEP3-expressing cells to produce cytotoxicity. Tamrintamab can be used in ovarian cancer research.
-
IMC-D11
0 ImagesCat. No.: HY-P991106Purity: 98.51%Synonyms: LY-3076226 antibodyIMC-D11 (LY-3076226 antibody) is an anti-FGFR3 IgG1 monoclonal antibody with an EC50 of approximately 0.1 nM against hFGFR3b and hFGFR3c. IMC-D11 inhibits the growth of FGFR3-dependent lung adenocarcinoma in mouse models and shows no effect on tumors that do not express FGFR3. IMC-D11 can serve as an ADC Antibody for ADC synthesis, such as LY3076226. IMC-D11 is applicable to research related to urothelial carcinoma, multiple myeloma, lung adenocarcinoma, as well as advanced or metastatic cancers.
-
Varsetatug
0 ImagesCat. No.: HY-P991723CAS No.: 3036004-28-8Synonyms: CX-2051 antibodyVarsetatug (CX-2051 antibody) is a humanized IgG1κ monoclonal antibody inhibitor targeting EpCAM/TROP1/CD326. Varsetatug serves as the antibody component of the ADC compound CX-2051. It can be used in research on cancers including breast cancer, prostate cancer and ovarian cancer.
-
Anti-FOLH1/PSMA Antibody (J591)
0 ImagesCat. No.: HY-P991359Purity: ≥99.0%Synonyms: MEDI3726 antibody; ADCT-401 antibodyAnti-FOLH1/PSMA Antibody (J591) (MEDI3726 antibody) is a human monoclonal antibody (mAb) targeting FOLH1/PSMA. Anti-FOLH1/PSMA Antibody (J591) can be used in Prostate cancer research.
-
Zevontabart
0 ImagesSynonyms: MYTX-011 Antibody; Q-397Zevontabart (MYTX-011 Antibody; Q-397) is a pH-dependent anti-c-MET antibody. Zevontabart regulates the trafficking process of c-MET to reduce receptor recycling, and enhances its own endocytosis and accumulation in c-MET-expressing cells. Zevontabart induces cytotoxicity in solid tumor cells and exerts anti-tumor activity in a non-small cell lung cancer xenograft mouse model. Zevontabart can be used to synthesize ADC, such as: MYTX-011. Zevontabart can be used in studies related to non-small cell lung cancer, with its corresponding isotype control being Human IgG1 kappa, Isotype Control (HY-P99001).
-
MEDI4276 Antibody
0 ImagesCat. No.: HY-P991238MEDI4276 Antibody is an HER2-targeted antibody, which can be used for the synthesis of the ADC molecule MEDI4276. MEDI4276 Antibody can be used in the study of cancer.
-
Iladatuzumab
0 ImagesCat. No.: HY-P99656CAS No.: 1906205-76-2Synonyms: MCDS0593AIladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research.
-
AMG-595 Antibody
0 ImagesCat. No.: HY-P991662CAS No.: 1607807-14-6AMG-595 Antibody is a EGFRvIII targeting antibody. AMG-595 Antibody can be used for synthesis of ADC AMG-595.
-
Renditatug
0 ImagesSynonyms: BAT8008 Antibody; BAT0806
-
Sacituzumab (powder)
0 ImagesCat. No.: HY-P99045ACAS No.: 1796566-95-4Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer.
-
OMTX005
0 ImagesCat. No.: HY-P991995Purity: 98.44%Synonyms: OMTX705 antibodyOMTX005 (OMTX705 antibody) is a humanized anti-FAP IgG1 monoclonal antibody that specifically binds to human (EC50: 0.33 nM)/mouse (EC50: 0.14 nM) FAP proteins and FAP-positive cells. OMTX005 exhibits no cytotoxicity when used alone and fails to induce an increase in caspase 3/7 activity in relevant cells. OMTX005 can be used to synthesize the ADC molecule OMTX705 for tumor research.
